	US 11,998,602 B2
	Methods for promoting myelination and for treating demyelinating diseases
Luke Lairson, San Diego, CA (US); Brittney Beyer, San Diego, CA (US); Mingliang Fang, Singapore (SG); and Gary Siuzdak, Cardiff, CA (US)
Assigned to The Scripps Research Institute, La Jolla, CA (US)
Appl. No. 16/978,558
Filed by The Scripps Research Institute, La Jolla, CA (US)
PCT Filed Nov. 13, 2018, PCT No. PCT/US2018/060793 § 371(c)(1), (2) Date Sep. 4, 2020, PCT Pub. No. WO2019/172969, PCT Pub. Date Sep. 12, 2019.
Claims priority of provisional application 62/640,151, filed on Mar. 8, 2018.
Prior Publication US 2021/0023218 A1, Jan. 28, 2021
Int. Cl. A61K 31/40 (2006.01); A61K 31/5415 (2006.01); A61K 45/06 (2006.01); A61P 25/00 (2006.01); C07C 303/02 (2006.01); C07K 16/28 (2006.01)

CPC A61K 45/06 (2013.01) [A61P 25/00 (2018.01); C07C 303/02 (2013.01); C07K 16/286 (2013.01)]

20 Claims

1. A method for treating or ameliorating one or more symptoms of a demyelinating disease in a subject, comprising administering to the subject (a) a pharmaceutical composition comprising a therapeutically effective amount of taurine or a taurine-like compound and (b) an agent that induces oligodendrocyte precursor cell (OPC) differentiation, thereby treating or ameliorating the symptoms of the demyelinating disease in the subject.